1. Home
  2. ONTF vs LXEO Comparison

ONTF vs LXEO Comparison

Compare ONTF & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ON24 Inc.

ONTF

ON24 Inc.

HOLD

Current Price

$8.10

Market Cap

347.2M

Sector

Technology

ML Signal

HOLD

Logo Lexeo Therapeutics Inc.

LXEO

Lexeo Therapeutics Inc.

HOLD

Current Price

$4.37

Market Cap

369.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONTF
LXEO
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
347.2M
369.8M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
ONTF
LXEO
Price
$8.10
$4.37
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
$8.10
$18.44
AVG Volume (30 Days)
986.7K
731.1K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
32.67
39.81
EPS
N/A
N/A
Revenue
$139,312,000.00
$654,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$3.60
52 Week High
$8.11
$10.99

Technical Indicators

Market Signals
Indicator
ONTF
LXEO
Relative Strength Index (RSI) 67.87 35.19
Support Level $7.84 N/A
Resistance Level N/A $7.90
Average True Range (ATR) 0.02 0.33
MACD -0.01 -0.04
Stochastic Oscillator 88.89 2.84

Price Performance

Historical Comparison
ONTF
LXEO

About ONTF ON24 Inc.

ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Share on Social Networks: